A Phase 4 interventional study of norepinephrine infused at the clinician's discretion and norepinephrine infused under computerized fuzzy logic control in Septic Shock, sponsored by Association pour le Développement de la Recherche et de l'Enseignement en Médecine d'Urgence. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-10-01.
Sponsored by Association pour le Développement de la Recherche et de l'Enseignement en Médecine d'Urgence · Phase 4, Interventional, and Treatment
The weaning rate of vasopressors drugs is usually chosen empirically by the clinician in critically patients. The investigators applied fuzzy logic principles to modify intravenous norepinephrine infusion rates during norepinephrine infusion in septic patients in order to reduce the duration of shock. The investigators goal was to reduce the duration of poorly controlled hemodynamic status.
862 studies on the registry are indexed under Shock, Septic; 207 are open to participants now.
This study's enrollment of 40 is below the median of 80 across 530 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →This is the only study on the registry with Association pour le Développement de la Recherche et de l'Enseignement en Médecine d'Urgence as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients were assigned to norepinephrine infused at the clinician's discretion.
Device: norepinephrine infused at the clinician's discretion
Patients were assigned to norepinephrine infused under computerized fuzzy logic control.
Device: norepinephrine infused under computerized fuzzy logic control
Time to shock resolution defined as cessation of vasopressor support
28 days survival, total amount of norepinephrine infused, duration of mechanical ventilation, and length of stay in the ICU
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.